课题基金 / 基金详情

NK Cells, Their Receptors and Unrelated Donor Transplant

NK Cells, Their Receptors and Unrelated Donor Transplant
NK 细胞、其受体和无关的供体移植
批准号:
7669395
负责人:
Jeffrey S. Miller
金额:
$210.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-08-17 至 2010-07-31

项目摘要

项目成果

Jeffrey S. Miller的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Recent trials of T-cell depleted haploidentical hematopoeitic cell transplantation (HCT) suggest that NK cell reactivity can lead o less GVHD, reduced risks of relapse and improved overall survival when NK cells are NOT inhabited by recipient KIR ligands. In a cohort of Unrelated Donor (URD) HCT recipients at the University of Minnesota, no survival advantage was seen, suggesting that differences in clinical settings or other components of the relevant immunotiology may account for these disparate clinical results. The main hypothesis to be tested in this Program is that NK cells are of biologic importance in URD transplantation and that killer immunoglobulin-like receptor (KIR) interactions with MHC class 1 ligands can alter the clinical outcomes. This Program includes a group of international experts in NK cell biology and bone marrow transplantation collaborating to investigate the relevance of NK alloreactivity in URD HCT, a setting where KIR repertoires differ in nearly all donor-recipient pairs. We will utilize the many thousands of blood and DNA samples available through the National Marrow Donor Program (NMDP) and their high quality long-term follow-up data available on transplant outcomes. Project 1 will focus on the physiologic role of KIR differences inherent between donors and recipients using increasingly higher resolution of KIR determinations from simple gene content to haplotype organization. Novel KIR allele polymorphisms will be identified from these studies and their clinical significance will be determined. However, in many patients, KIR are not expressed normally after transplant. Therefore, in Project 2, NK cell development, the acquisition of functional KIR and the mechanisms that determine KIR expression will be studied. The retrospective NMDP cohort studies will facilitate immediate bedside to bench studies for Projects 1 and 2. In Project 3, prospective trials will exploit NK cell reactivity clinically and facilitate prospective evaluation of KIR genotype and KIR development based upon the work of Projects 1 and 2. Additionally, higher resolution KIR genotyping and matching will be studied for their impact on the risks of clinical complications after HCT. The synergistic interaction between all projects will take basic NK biology from the bench to the bee side to improve outcomes of URD HCT by better donor selection, KIR repertoire manipulation or enhancement of NK cell development. In addition to Administration (A) and Biostatistics (B) Cores, the projects are supported by scientific cores, each integrating with all projects for KIR genotyping (Core C), K.IR haplotype sequencing (Core D) and a KIR sequence public database (Core E). Taken together, these highly focused and integrated studies vv 11 definitively assess the role of NK cells and their receptors in URD IICT and broaden the success of alternative donor transplant, the only potentially curative therapy for many patients with advanced cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors
  • 批准号:
    10735554
  • 项目类别:
  • 资助金额:
    $92.85万
  • 财政年份:
    2023
  • 负责人:
    Jeffrey S. Miller
  • 依托单位:
Viral priming and targeting NK cells against solid tumor malignancies
  • 批准号:
    9319717
  • 项目类别:
  • 资助金额:
    $91.2万
  • 财政年份:
    2015
  • 负责人:
    Jeffrey S. Miller
  • 依托单位:
Viral priming and targeting NK cells against solid tumor malignancies
  • 批准号:
    8952308
  • 项目类别:
  • 资助金额:
    $91.2万
  • 财政年份:
    2015
  • 负责人:
    Jeffrey S. Miller
  • 依托单位:
Viral priming and targeting NK cells against solid tumor malignancies
  • 批准号:
    10219166
  • 项目类别:
  • 资助金额:
    $91.2万
  • 财政年份:
    2015
  • 负责人:
    Jeffrey S. Miller
  • 依托单位:
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
  • 批准号:
    82072862
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2020
  • 负责人:
    徐云升
  • 依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 项目类别:
    面上项目
  • 资助金额:
    53.0万元
  • 批准年份:
    2020
  • 负责人:
    徐西振
  • 依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
  • 批准号:
    81903002
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.5万元
  • 批准年份:
    2019
  • 负责人:
    王斐斐
  • 依托单位: